

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)*

A.B. Kimball,¹ C. Leonardi,² M. Stahle,³ W. Gulliver,⁴ M. Chevrier,⁵ S. Fakharzadeh,⁵ K. Goyal,⁵ S. Calabro,⁵ W. Langhoff⁶ and A. Menter,⁷ on behalf of the PSOLAR Steering Committee**

¹Harvard Medical School and Massachusetts General Hospital, Boston, MA, U.S.A.

²St. Louis University, St. Louis, MO, U.S.A.

³Karolinska Institutet, Stockholm, Sweden

⁴Memorial University of Newfoundland and New Lab Life Sciences, St. John's, NL, Canada

⁵Janssen Scientific Affairs, LLC, Horsham, PA, U.S.A.

⁶Janssen Research & Development, LLC, Horsham, PA, U.S.A.

⁷Baylor University Medical Center, Dallas, TX, U.S.A

Summary

Correspondence

Alexa B. Kimball.

E-mail: harvardskinstudies@partners.org

Accepted for publication

25 March 2014

Funding sources

The Psoriasis Longitudinal Assessment and Registry (PSOLAR) is sponsored by Janssen Scientific Affairs, LLC, Horsham, PA, U.S.A.

Conflicts of interest

See Appendix 1.

*Plain language summary available online

**PSOLAR Steering Committee members are listed in Appendix 2.

DOI 10.1111/bjd.13013

Background Psoriasis is associated with several comorbidities and behavioural risk factors.

Objectives To evaluate demographic and disease characteristics in patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Methods PSOLAR is a global, prospective, longitudinal, disease-based registry that includes a postmarketing commitment to evaluate safety in patients with psoriasis. Enrolled patients had to be receiving, or be eligible to receive, conventional systemic or biological agents. Demographic/disease characteristics, medical histories, lifestyle risk factors and previous treatments are collected at enrolment. Efficacy and safety data are collected every 6 months for 8 years, and data are extracted annually. Selected parameters are evaluated by age quartile using post hoc analyses.

Results As of 23 August 2012, 11 900 patients were enrolled at 301 sites in North America, Europe and Latin America. Over half of the PSOLAR population (54.7%) is male, with a mean age of 48.6 years and mean body mass index of 30.9 kg m⁻² at enrolment. Mean duration of disease at enrolment was 17.5 years, and mean Physician's Global Assessment score was 2.0. Psoriatic arthritis (35.5%) and cardiovascular diseases (38.2%) were highly prevalent. Diabetes mellitus type II was reported in 11.4% of patients. Depression and anxiety were noted in 14.7% and 11.1% of patients, respectively; 79.0% reported any alcohol use and 56.7% reported smoking or a history of smoking. The occurrence of most comorbidities, including cardiovascular disease and risk factors, increased with age.

Conclusions In the PSOLAR population, multiple and age-appropriate comorbidities are associated with psoriasis and may affect the selection of psoriasis treatments.

What's already known about this topic?

- Psoriasis is a complicated disorder, often accompanied by multiple comorbidities.
- Demographic and disease characteristics of patients with psoriasis reported from large claims datasets may be affected by misclassification bias or coding errors.
- In clinical trials, many patients are excluded owing to strict inclusion criteria.

What does this study add?

- Data collected by the Psoriasis Longitudinal Assessment and Registry reveal that the demographics and disease characteristics of patients with psoriasis who are receiving, or are candidates for, systemic therapy in actual clinical care resemble those reported in clinical trials.
- Most comorbidities occur more frequently in older patients, who, in turn, may require more comprehensive overall medical care.

Psoriasis is a common, chronic, inflammatory, immune-mediated disease that manifests with scaly, erythematous plaques on the skin.¹ Psoriatic disease is often associated with a variety of comorbid conditions, including psoriatic arthritis (PsA), which has been estimated to occur in one-third of patients with psoriasis.² Likewise, cardiovascular conditions and risk factors, including diabetes, hypertension, hyperlipidaemia, obesity and metabolic syndrome, as well as chronic pulmonary disease and Crohn disease, are commonly reported among patients with psoriasis.^{3–10} Patients with psoriasis have an increased risk of depression and anxiety compared with the general population,¹¹ and lifestyle risk factors that may exacerbate psoriasis itself or complications of the disease, such as smoking and alcohol use, are highly prevalent in this patient population.¹²

Current understanding of the typical profile of a patient with psoriasis, including demographic and disease characteristics, as well as common comorbidities and standard-of-care treatment, is based mainly on large datasets derived from claims databases or populations enrolled in clinical trials. However, such studies have limitations, including coding accuracy and criteria required for enrolment, respectively.¹³ Although patient registries may also have limitations, such as participation, recall and other forms of bias, such observational studies allow for the collection of valuable data during continuous treatment in actual practice settings.^{14,15}

The Psoriasis Longitudinal Assessment and Registry (PSOLAR) is a large, international, longitudinal, disease-based registry with prospective enrolment of patients with psoriasis who are receiving, or are candidates for treatment with, systemic therapies.¹⁶ This observational study, which supports a postmarketing commitment of the sponsor (Janssen Scientific Affairs, LLC, Horsham, PA, U.S.A.), provides the opportunity to collect epidemiological data on patients with psoriasis who are treated in real-life dermatological practices primarily in North America and Europe. This report provides a comprehensive description of demographics, disease characteristics, medical history, lifestyle risk factors (i.e. alcohol use and smoking) and treatments prior to enrolment in PSOLAR. These data are further analysed to determine how the prevalence of certain comorbidities and social behaviours commonly observed in patients with psoriasis may vary with age.

Methods

PSOLAR is a prospective, 8-year, longitudinal, disease-based registry designed to collect safety, clinical outcome, quality of

life and comorbidity data from patients with psoriasis who are receiving, or are eligible to receive, conventional systemic or biological therapies. PSOLAR patients are enrolled at nearly 300 academic, community-based and hospital-affiliated clinical practices in 16 countries.¹⁶ To meet the need for postmarketing surveillance of the long-term safety of psoriasis therapies developed by the sponsor within the registry population, enrolment was planned for approximately 12 000 patients and to accommodate patients exposed to not only sponsor-produced biologics (i.e. ustekinumab and infliximab), but also other biological agents (e.g. adalimumab and etanercept), as well as other nonbiological therapies (e.g. immunomodulators and/or phototherapy).

The design and utility of PSOLAR, as well as the role of the chartered Steering Committee (see Appendix 2), have been reported previously.¹⁶ PSOLAR was conducted in accordance with guidelines from the Agency for Healthcare Research and Quality.¹⁷ Briefly, eligible patients (aged ≥ 18 years) must have had a diagnosis of moderate-to-severe plaque or other form of psoriasis for which they were receiving, or were candidates for receiving, treatment with systemic therapies. As with all observational studies, study physicians prescribe treatment based solely on the usual practices of care. The registry does not allocate patients to specific treatment or restrict the use of commercially available medications as monotherapy or in combination. Sites collect a core set of data that includes demographics, disease activity, medical history and previous medications at enrolment; safety data are collected at each study visit every 6 months for a minimum of 8 years.

Specified data are collected by site personnel using the following methods: (i) direct contact (i.e. office visit or, in limited circumstances, by telephone) with the patient; (ii) review of the patient's medical records; or (iii) contact with the patient's primary care physician or specialty physician involved in the patient's medical care. Data collected at each site include demographic and disease characteristics, medical histories, lifestyle risk factors, and previous medication exposure using electronic case report forms, which were designed to query for specific parameters and offered the option to provide additional information for certain queries. For example, patients were queried for the presence of PsA and, if present, they were asked if the diagnosis of PsA had been confirmed by a joint specialist.

For this report, epidemiological data (i.e. demographic and disease characteristics, individual and family medical history,

social activity history and psoriasis treatment history) at enrolment, as well as history of infection requiring prescription treatment in the 3 years prior to enrolment, were summarized using descriptive statistics. Selected parameters [i.e. body mass index (BMI), medical history and social activity] were summarized by age quartiles of 18–35 years (Q1), 36–50 years (Q2), 51–65 years (Q3) and > 65 years (Q4). This report includes data for patients enrolled prior to the annual database extract on 23 August 2012.

Results

As of the 23 August 2012 PSOLAR data extract, 11 900 of the 12 000 targeted patients were enrolled at 301 global sites in North America, Europe and Latin America. The first patient was enrolled on 20 June 2007. More than 90% of sites are located in North America (i.e. approximately 75.0% in the U.S.A. and approximately 16.0% in Canada) (Fig. 1).

At enrolment, the mean patient age was 48.6 years and the mean BMI was 30.9 kg m⁻² (Table 1). Just over half of the PSOLAR population at this time were men (54.7%), with the majority being white (83.1%). Approximately 80.0% of patients in PSOLAR were either overweight or obese at enrolment. Based on the National Heart, Lung, and Blood Institute Obesity Education Initiative criteria, nearly half of the patients were obese at enrolment: 24.3% were of class I obesity status (BMI 30.0–34.9), 13.1% were of class II obesity status (BMI 35.0–39.9) and 10.8% were of class III obesity status (BMI ≥ 40); an additional 32.1% of patients were overweight.

Disease characteristics

The mean percentage of body surface area (BSA) affected by psoriasis was 12.1% at enrolment, which is significantly lower than the mean BSA affected at peak historical disease activity (29.7%) (Table 2). This finding is consistent with the fact that many patients were receiving treatment for psoriasis at the

Table 1 Demographic and disease characteristics at enrolment (enrolled patients)

Patients enrolled	n = 11 900
Sex, male	6513 (54.7)
Race, white	9890/11 898 (83.1)
Age (years)	48.6 ± 13.9
BMI (kg m ⁻²)	30.9 ± 7.2
BMI category ^a	11 703
Underweight (BMI < 18.5)	59 (0.5)
Normal (BMI 18.5–24.9)	2235 (19.1)
Overweight (BMI 25.0–29.9)	3762 (32.1)
Obesity class I (BMI 30.0–34.9)	2845 (24.3)
Obesity class II (BMI 35.0–39.9)	1537 (13.1)
Obesity class III (BMI ≥40.0)	1265 (10.8)
Psoriasis type	11 854
Plaque	11 491 (96.9)
Other	1089 (9.2)
Duration of psoriasis (years)	11 777
Mean ± SD	17.5 ± 13.5

Values are n (%) of patients or mean ± SD. BMI, body mass index. ^aObesity class based upon National Heart, Lung, and Blood Institute Obesity Education Initiative (<http://www.nhlbi.nih.gov/about/oei/>).

time of registry enrolment. Similarly, the mean Physician’s Global Assessment (PGA) score was 2.0 at entry compared with 3.1 at peak activity. Approximately three quarters of patients had a mean PGA score indicative of minimal (1), mild (2) or moderate (3) psoriasis at enrolment (23.2%, 28.1% and 27.5%, respectively), whereas almost all patients had moderate (46.4%), marked (26.4%) or severe (7.0%) psoriasis at peak disease activity. Overall, 96.9% of patients enrolled in PSOLAR had plaque psoriasis (Table 1). The mean time since psoriasis had been diagnosed was 17.5 years, and the mean time since the highest degree of disease activity was 3.3 years.

Comorbidities and family history

Approximately one-third of patients (35.5%; n = 4226) reported a history of PsA at the time of enrolment in PSOLAR (Table 3), with 1664 patients (14.1%) having their diagnosis confirmed by a joint specialist. A family history of psoriasis was reported by 45.5% of patients, while 10.3% noted a family history of PsA (Table 4). There was a high proportion of patients (38.2%) with a history of cardiovascular disease [e.g. myocardial infarction (2.4%), transient ischaemic attack or stroke (1.2%), and congestive heart failure (1.0%)] and risk factors [e.g. hypertension (29.7%), hyperlipidaemia (18.6%) and diabetes mellitus type II (11.4%)] (Table 3), with a family history of cardiovascular disease reported by 44.7% of patients (Table 4).

A history of pulmonary conditions was reported for 14.4% of patients [e.g. asthma (8.0%) and sleep apnoea (5.7%)], while a history of hepatic conditions [e.g. cirrhosis (0.8%), hepatitis B (0.5%) and hepatitis C (1.1%)] was noted in < 5.0% of patients (Table 3). Liver biopsies had been per-




Fig 1. Proportion of patients enrolled in the Psoriasis Longitudinal Assessment and Registry by country.

Table 2 Disease activity at enrolment and peak historical level (enrolled patients)

	All patients	Patients with peak historic data	
		Enrolment ^a	Peak historic
BSA by palm method	11 756	6746	6772
Mean ± SD	12.1 ± 17.5	13.6 ± 19.04	29.7 ± 24.8
PGA score	11 360	6606	6845
Mean ± SD	2.0 ± 1.2	2.0 ± 1.22	3.1 ± 1.0
PGA score distribution	11 360	6606	6845
0 = clear	1335 (11.8)	767 (11.6)	171 (2.5)
1 = minimal	2633 (23.2)	1544 (23.4)	258 (3.8)
2 = mild	3196 (28.1)	1782 (27.0)	959 (14.0)
3 = moderate	3125 (27.5)	1835 (27.8)	3174 (46.4)
4 = marked	873 (7.7)	548 (8.3)	1807 (26.4)
5 = severe	198 (1.7)	130 (2.0)	476 (7.0)

Values are n (%) of patients or mean ± SD. BSA, body surface area affected by psoriasis; PGA, Physician's Global Assessment. ^aIncludes patients for whom data were also collected for peak disease activity.

formed in 1.9% of the patients (n = 223), and only 0.3% of patients (n = 31) had a history of alcoholic liver disease. A history of ulcerative colitis (0.8%) or Crohn disease (0.5%) was rarely noted. Similarly, low proportions of patients with neurological conditions, including demyelinating disease (0.2%) and multiple sclerosis (0.1%), and other autoimmune conditions, such as lupus (0.3%), were observed.

Overall, 24.6% of patients reported significant infections requiring prescription medication within the 3-year interval before enrolment. Most prior infections were bacterial in nature (21.6%); opportunistic infections (as defined by the site investigator) were uncommon (1.2%). A history of basal cell (BCC) and squamous cell carcinoma (SCC) was reported for 3.8% and 2.4% of patients, respectively, and a history of other cancers was reported in 3.7% of patients (Table 3), including lymphoma (n = 14) in approximately 0.1% of patients. A history of psychiatric disease was noted in 20.7% of patients. Among the psychiatric conditions commonly associated with psoriasis, depression was reported for 14.7% of patients and anxiety for 11.1% (Table 3). High proportions of patients reported current or previous alcohol use of any kind (79.0%), or smoking in any capacity (56.7%) (Table 5).

Previous treatment

At enrolment, 97.3% of patients had been treated with topical therapy, 54.6% with phototherapy and 43.6% with retinoids, such as acitretin (19.9%), and 47.6% with immunomodulators, such as methotrexate (40.6%) and ciclosporin (15.6%) (Table 6). Nearly three-quarters (72.1%) had received biological therapy prior to entry into the registry: 39.0% had received one biological agent and 29.3% had received two or three biological agents. Specific biological agents received by patients enrolled in PSOLAR prior to enrolment included etanercept (40.5%), adalimumab (29.4%), ustekinumab (18.7%), infliximab (15.2%), efalizumab (11.2%), alefacept (5.8%) and/or others (2.3%).

Baseline characteristics by age quartile

Selected baseline characteristics were analysed by age quartiles of 18–35 years (Q1), 36–50 years (Q2), 51–65 years (Q3) and > 65 years (Q4). Mean BMI values were comparable in the Q1 (29.5), Q2 (31.4), Q3 (31.5) and Q4 (30.1) groups (Table 7). The proportions of patients with class I obesity status increased consistently with age, but only by a few percentage points, while the Q1 (youngest) and Q4 (oldest) groups had similar and slightly lower proportions of patients with class II/III obesity status.

The proportion of patients that reported PsA was lowest in the Q1 group (23.6%), and comparably higher among the Q2 (37.2%), Q3 (40.7%) and Q4 (35.0%) groups (Table 8). The proportion with a history of cardiovascular disease and risk factors generally increased with age. The same trend was observed for most other medical history categories and individual diseases. Of note, the proportion of patients with diabetes mellitus II was noticeably lower for the Q1 (2.3%) and Q2 (7.1%) age groups compared with the Q3 (17.5%) and Q4 (21.2%) age groups, as were those with hypertension and hyperlipidaemia.

Finally, the proportions of patients with a history of overall psychiatric disease increased slightly with age across the Q1, Q2 and Q3 groups; a similar pattern was observed for history of depression (Table 9). In contrast, generally similar proportions of patients with a history of anxiety, bipolar disorder and suicidal ideation were observed across age groups. The proportions of patients reporting current use of alcohol or identified as current smokers generally decreased with age, while the proportions of those who had stopped using alcohol or smoking consistently increased with age (Table 9).

Discussion

PSOLAR, which began in 2007, is a prospective, longitudinal, disease cohort study for patients with psoriasis who are eligi-

Table 3 Medical history at enrolment (enrolled patients)

Patients enrolled ^a	n = 11 900
Psoriatic arthritis	4226 (35.5)
Cardiovascular disease	4545 (38.2)
Hypertension	3527 (29.7)
Hyperlipidaemia	2215 (18.6)
Atherosclerotic disease	417 (3.5)
Coronary artery disease	355 (3.0)
Myocardial infarction	290 (2.4)
Angina ^b	165 (1.4)
TIA/stroke	148 (1.2)
Congestive heart failure	122 (1.0)
Peripheral arterial disease	68 (0.6)
Psychiatric disease	2460 (20.7)
Depression	1751 (14.7)
Anxiety	1318 (11.1)
Bipolar	181 (1.5)
Suicidal ideation	114 (1.0)
Endocrine disease	2233 (18.8)
Diabetes mellitus type II	1357 (11.4)
Thyroid dysfunction	910 (7.7)
Diabetes mellitus type I	145 (1.2)
Pulmonary disease	1710 (14.4)
Asthma	952 (8.0)
Sleep apnoea	680 (5.7)
COPD	241 (2.0)
NMSC ^c	657 (5.5)
Basal cell carcinoma	446 (3.8)
Squamous cell carcinoma	287 (2.4)
Melanoma skin cancer	103 (0.9)
Other types of cancer ^d	439 (3.7)
Hepatic disease	485 (4.1)
Hepatitis C	129 (1.1)
Cirrhosis	90 (0.8)
Drug-induced ^e	71 (0.6)
Hepatitis B	65 (0.5)
Inflammatory bowel disease	273 (2.3)
Indeterminate colitis	106 (0.9)
Ulcerative colitis	96 (0.8)
Crohn disease	58 (0.5)

Values are n (%) of patients for conditions occurring at an incidence of at least 0.5%. TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease; NMSC, nonmelanoma skin cancer. ^aOn the case report form all patients (n = 11 900) provided a response regarding psoriatic arthritis status, whereas 11 888 patients reported the presence of other relevant medical history. ^bMay include noncardiac angina (e.g. bowel angina) if not specified by site. ^cSome patients had both basal and squamous cell carcinoma, accounting for the discrepancy between the total proportion with NMSC and the proportions with individual types of skin cancer. ^dOther types of cancer were entered manually on the case report form at each study site. A history of other cancers reported in a total of five or more patients included lymphoma (n = 14), breast (n = 13), gynaecological (n = 10), cervical (n = 8), colorectal (n = 8), prostate (n = 7), bladder (n = 6), kidney (n = 6) and sarcoma (n = 6). ^eIncludes drug-induced hepatic disease related to psoriasis or other treatment.

Table 4 Family medical history at enrolment (enrolled patients)

Number of patients with family history data	n = 11 540
Psoriasis	5246 (45.5)
Psoriatic arthritis	1193 (10.3)
Cardiovascular disease	5158 (44.7)
NMSC	1250 (10.8)
Melanoma skin cancer	624 (5.4)
Other cancer	3839 (33.3)
Diabetes	4450 (38.6)
Inflammatory bowel disease	762 (6.6)
Indeterminate colitis	200 (1.7)
Ulcerative colitis	153 (1.3)
Crohn disease	199 (1.7)
Sprue/coeliac disease	42 (0.4)

Values are n (%) of patients. NMSC, nonmelanoma skin cancer.

Table 5 Social activity at enrolment (enrolled patients)

Patients enrolled	n = 11 900
Alcohol	11 875
Never used	2500 (21.1)
Current use	7678 (64.7)
Have used alcohol and stopped	1697 (14.3)
Smoking	11 882
Never smoked	5139 (43.3)
Current smoker	2831 (23.8)
Have smoked and stopped	3912 (32.9)

Values are n (%) of patients.

ble for systemic therapy. With 11 900 patients enrolled at 301 global centres as of the August 2012 database extract, PSOLAR represents the largest, international, industry-sponsored collection of data from a disease-based registry of patients with psoriasis. As part of postmarketing commitments to evaluate safety, a primary objective for PSOLAR is to provide pharmacovigilance reports to regulatory agencies for individual sponsor products. However, the registry also provides data on patients receiving multiple other therapies and offers relevant information about the disease to the community of healthcare providers treating patients with psoriasis. Our findings confirm that psoriasis is a complex disease frequently associated with multiple and age-appropriate comorbidities, which should be considered when evaluating treatment for psoriasis.

The PSOLAR population represents one with substantial disease, as indicated by peak historic disease activity (mean PGA score 3.1, but mean BSA of 29.7%) which, on average, predated enrolment by about 3 years. At entry, patients had somewhat less severe disease compared with peak historic levels (mean PGA 2.0, mean BSA 12.1%), a not unexpected finding given that the majority of patients were receiving treatment for psoriasis at the time of enrolment. The majority of patients had plaque psoriasis, and nearly half (45.5%) had a family history of psoriasis. Overall, 35.5% reported a history of PsA at enrolment, consistent with similar populations with

Table 6 Previous medication use at enrolment (enrolled patients)

Patients enrolled	n = 11 900
Number of patients with data available	11 866
Topical therapy	11 542 (97.3)
Tazarotene	1309 (11.0)
Calcipotriene/betamethasone	2904 (24.5)
Topical steroid therapy	11 267 (95.0)
High potency	9570 (80.7)
Medium potency	7032 (59.3)
Low potency	4576 (38.6)
Phototherapy	6482 (54.6)
Psoralen plus UVA	2028 (17.1)
UVB	5438 (45.8)
Systemic steroids	2782 (23.4)
Retinoids	5176 (43.6)
Acitretin	2359 (19.9)
Immunomodulators	5646 (47.6)
Ciclosporin	1855 (15.6)
Methotrexate	4819 (40.6)
Other immunomodulators	317 (2.7)
Biological agents(s)	8583 (72.1)
Infliximab	1808 (15.2)
Ustekinumab	2220 (18.7)
Adalimumab	3495 (29.4)
Alefacept	696 (5.8)
Efalizumab	1328 (11.2)
Etanercept	4814 (40.5)
Other biological agents	277 (2.3)
Number of biological agents used prior to entry	
0	3317 (27.9)
1	4645 (39.0)
2–3	3490 (29.3)
4–7	448 (3.8)

Values are n (%) of patients for treatments received by at least 2.0% of patients. UVA, ultraviolet A; UVB, ultraviolet B.

moderate-to-severe psoriasis.^{2,18} About 10.0% reported a family history of PsA, although only about 15.0% of patients had PsA diagnosed by a joint specialist. PSOLAR includes a broad spectrum of patients with psoriasis who may or may not be normally eligible for clinical trials. Many demographic features of the PSOLAR population reported at enrolment (e.g. age) and

disease characteristics (e.g. % BSA) reported at peak historic levels are generally similar to those reported in phase III clinical trials and other observational studies of biologics in psoriasis, while others (e.g. male : female ratio) may differ.^{19–27} Interestingly, the proportion of women enrolled in PSOLAR and other observational studies of biological agents was 10.0–15.0% higher than that reported in many clinical trials, which may be because women of childbearing age are less inclined to participate in studies of experimental agents.

Based upon National Heart, Lung, and Blood Institute Obesity Education Initiative criteria, about 20% of patients were of normal body weight status at enrolment in PSOLAR, while a remarkable 80% were overweight or obese. Furthermore, the rate of obesity at entry into PSOLAR (48.2%) is higher than published rates for adults in the U.S.A. and Canada (nearly 25.0% and 35.0%, respectively).²⁸ This is particularly notable because increased BMI is an established risk factor for cardiovascular disease,²⁹ may impact response to treatment, and could further burden patients with anxiety, depression and sleep impairment.³⁰ Interestingly, the prevalence of weight problems did not differ much across age quartiles, while the prevalence of cardiovascular risk factors varied substantially, suggesting a tendency towards accumulation of these comorbidities over time.

There was a high prevalence of cardiovascular disease (38.2%) and other cardiovascular risk factors, including hypertension (29.7%), hyperlipidaemia (18.6%) and diabetes mellitus type II (11.4%), all of which, along with obesity, are components of metabolic syndrome. These results are consistent with the reported association between psoriasis and both cardiovascular risk factors and metabolic syndrome.^{31–33} Of note, the prevalence of cardiovascular risk factors increased substantially with increasing age, which indicates, as expected, that cardiovascular comorbidities tend to accumulate over time in the psoriasis population. Furthermore, high proportions of patients reported a family history of cardiovascular disease (44.7%) and diabetes (38.6%), likely indicative of a predisposition to such diseases in certain patients with psoriasis.

Some patients reported a history of pulmonary diseases [e.g. asthma (8.0%), sleep apnoea (5.7%) and chronic

Table 7 Body mass index (BMI) and obesity class by age quartiles (enrolled patients)

Age (years)	18–35	36–50	51–65	> 65
BMI (kg m ⁻²)	2285	4003	4073	1339
Mean ± SD	29.5 ± 7.58	31.4 ± 7.57	31.5 ± 6.86	30.1 ± 6.17
Obesity class ^a	2285	4003	4073	1339
Underweight (BMI < 18.5)	28 (1.2)	18 (0.4)	6 (0.1)	7 (0.5)
Normal (BMI 18.5–24.9)	682 (29.8)	685 (17.1)	622 (15.3)	246 (18.4)
Overweight (BMI 25.0–29.9)	676 (29.6)	1293 (32.3)	1310 (32.2)	481 (35.9)
Obesity class I (BMI 30.0–34.9)	444 (19.4)	968 (24.2)	1071 (26.3)	361 (27.0)
Obesity class II (BMI 35.0–39.9)	243 (10.6)	532 (13.3)	619 (15.2)	143 (10.7)
Obesity class III (BMI ≥40.0)	212 (9.3)	507 (12.7)	445 (10.9)	101 (7.5)

Values are n (%) of patients, unless otherwise noted, for conditions occurring at a total incidence of at least 0.5% in any quartile. ^aObesity class based upon National Heart, Lung, and Blood Institute Obesity Education Initiative (<http://www.nhlbi.nih.gov/about/oei/>).

Table 8 Medical history by age quartiles (enrolled patients)

Age (years)	18–35	36–50	51–65	> 65
Patients with PsA data available (n)	2322	4075	4147	1352
Patients with PsA (n)	548 (23.6)	1517 (37.2)	1687 (40.7)	473 (35.0)
Patients with relevant medical history data (n)	2321	4068	4144	1352
Cardiovascular disease	223 (9.6)	1193 (29.3)	2213 (53.4)	916 (67.8)
Hypertension	160 (6.9)	880 (21.6)	1747 (42.2)	740 (54.7)
Hyperlipidaemia	86 (3.7)	560 (13.8)	1109 (26.8)	460 (34.0)
Atherosclerotic disease	3 (0.1)	49 (1.2)	217 (5.2)	148 (10.9)
Peripheral arterial disease	0	7 (0.2)	36 (0.9)	25 (1.8)
Coronary artery disease	3 (0.1)	40 (1.0)	183 (4.4)	129 (9.5)
Myocardial infarction	2 (0.1)	46 (1.1)	137 (3.3)	105 (7.8)
Angina ^a	3 (0.1)	18 (0.4)	90 (2.2)	54 (4.0)
TIA/stroke	2 (0.1)	23 (0.6)	64 (1.5)	59 (4.4)
Congestive heart failure	6 (0.3)	17 (0.4)	53 (1.3)	46 (3.4)
Endocrine disease	135 (5.8)	535 (13.2)	1112 (26.8)	450 (33.3)
Diabetes mellitus II	54 (2.3)	290 (7.1)	726 (17.5)	286 (21.2)
Thyroid dysfunction	73 (3.1)	233 (5.7)	420 (10.1)	184 (13.6)
Diabetes mellitus I	14 (0.6)	47 (1.2)	62 (1.5)	22 (1.6)
Pulmonary disease	246 (10.6)	526 (12.9)	678 (16.4)	260 (19.2)
Asthma	207 (8.9)	302 (7.4)	318 (7.7)	125 (9.2)
Sleep apnoea	39 (1.7)	225 (5.5)	325 (7.8)	91 (6.7)
COPD	3 (0.1)	30 (0.7)	132 (3.2)	76 (5.6)
NMSC ^b	6 (0.3)	80 (2.0)	327 (7.9)	244 (18.0)
Basal cell carcinoma	5 (0.2)	60 (1.5)	227 (5.5)	154 (11.4)
Squamous cell carcinoma	1 (< 0.1)	20 (0.5)	137 (3.3)	129 (9.5)
Other types of cancer ^c	13 (0.6)	60 (1.5)	204 (4.9)	162 (12.0)
Hepatic disease	37 (1.6)	140 (3.4)	231 (5.6)	77 (5.7)
Hepatitis C	5 (0.2)	41 (1.0)	71 (1.7)	12 (0.9)
Cirrhosis	5 (0.2)	20 (0.5)	48 (1.2)	17 (1.3)
Drug-induced ^d	9 (0.4)	21 (0.5)	30 (0.7)	11 (0.8)
Hepatitis B	1 (< 0.1)	26 (0.6)	30 (0.7)	8 (0.6)
Inflammatory bowel disease	37 (1.6)	77 (1.9)	117 (2.8)	42 (3.1)
Crohn disease	17 (0.7)	22 (0.5)	18 (0.4)	1 (0.1)
Ulcerative colitis	10 (0.4)	28 (0.7)	41 (1.0)	17 (1.3)
Indeterminate colitis	9 (0.4)	25 (0.6)	52 (1.3)	20 (1.5)

Values are n (%) of patients, unless otherwise noted, for conditions occurring at a total incidence of at least 0.5% in any quartile. PsA, psoriatic arthritis; TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease; NMSC, nonmelanoma skin cancer. ^aMay include noncardiac angina (e.g. bowel angina) if not specified by site. ^bSome patients had both basal and squamous cell carcinoma, accounting for the discrepancy between the total proportion with NMSC and the proportions with individual types of skin cancer. ^cOther types of cancer were entered manually on the case report form at each study site. A history of other cancers reported in a total of five or more patients included lymphoma (n = 14), breast (n = 13), gynaecological (n = 10), cervical (n = 8), colorectal (n = 8), prostate (n = 7), bladder (n = 6), kidney (n = 6) and sarcoma (n = 6). ^dIncludes drug-induced hepatic disease related to psoriasis or other treatment.

obstructive pulmonary disease (COPD; 2.0%)] at enrolment. While other reports have suggested an association between COPD and psoriasis, the proportion of patients with a history of COPD observed in PSOLAR is lower than that reported for patients with psoriasis elsewhere.^{34,35} Generally, COPD occurs more commonly than asthma, and studies evaluating an association between psoriasis and asthma have been inconclusive.³⁶ However, in PSOLAR, the higher prevalence of asthma (8.0%) compared with COPD is likely attributable to a reporting bias due to the overlap of clinical symptoms between

COPD and asthma. The approximately 6.0% of patients reporting a history of sleep apnoea is likely related to the high prevalence of obesity.

As reported elsewhere, there may be an increase in the background risk of cancer in patients with psoriasis.^{36,37} Increased rates of lymphoma have been reported in multiple cohort studies of patients with psoriasis,⁴ and the risk of lymphoma with biological agents, in general, remains a topic of debate.³⁸ In PSOLAR, about 4% of patients had a history of some type of cancer other than melanoma and nonmelanoma

Age (years)	18–35	36–50	51–65	> 65
Psychiatric disease ^a	411 (17.7)	830 (20.4)	966 (23.3)	252 (18.6)
Depression	269 (11.6)	588 (14.5)	716 (17.3)	177 (13.1)
Anxiety	252 (10.9)	450 (11.1)	487 (11.8)	129 (9.5)
Bipolar disorder	40 (1.7)	69 (1.7)	62 (1.5)	10 (0.7)
Suicidal ideation	20 (0.9)	44 (1.1)	41 (1.0)	9 (0.7)
Social activity				
Alcohol use	2316	4068	4140	1348
Current use of alcohol	1585 (68.4)	2757 (67.8)	2608 (63.0)	726 (53.9)
Have used alcohol and stopped	237 (10.2)	543 (13.3)	669 (16.2)	248 (18.4)
Smoking	2320	4069	4142	1348
Current smoker	700 (30.2)	1113 (27.4)	862 (20.8)	156 (11.6)
Have smoked and stopped	478 (20.6)	1106 (27.2)	1651 (39.9)	677 (50.2)

Values are n (%) of patients. ^aIncludes psychiatric conditions occurring in at least 0.5% of patients.

Table 9 Psychiatric disease history and lifestyle risk factors by age quartiles (enrolled patients)

skin cancer (NMSC), while approximately one-third of patients had a family history of such cancers. A history of NMSC was reported in 5.5% of patients: 3.8% with BCC and 2.4% with SCC, with some patients having had both BCC and SCC. Although the ratio of BCC to SCC in the general population is reported to be 4 : 1³⁹, exposure to psoralen with ultraviolet A (17.0%), as well as immunosuppressive agents, in some patients in PSOLAR could have increased the risk for SCC,⁴⁰ and a potential reporting bias that could lead to under-reporting of BCC among dermatologists may have shifted the expected balance between BCC and SCC.

A history of hepatic disorders was noted in < 5% of patients enrolled in PSOLAR, although other reports have suggested a notably higher prevalence of liver diseases, particularly nonalcoholic fatty liver disease, among patients with psoriasis.^{41,42} The lower prevalence observed in the PSOLAR population may reflect the design of the case report form, which allows for proactive inquiry about only certain hepatic conditions. Prior liver biopsies were reported in about 2.0% of patients. Although the reason for biopsy was not captured, the majority were presumably performed to monitor for liver toxicity in patients receiving methotrexate, as per published guidelines.⁴³

An increased risk of psoriasis has been reported in patients with Crohn disease and ulcerative colitis; common inflammatory, and even genetic, pathways have been implicated as possible causes.^{44,45} Among patients enrolled in PSOLAR, the prevalence is 0.5% for Crohn disease and 0.8% for ulcerative colitis. Similar findings were reported in a large, case-control study, in which 0.5% of patients with psoriasis reported a history of ulcerative colitis at baseline compared with 0.3% of age- and sex-matched controls, while the prevalence of Crohn disease among patients with psoriasis was 0.5% vs. 0.2% for controls.⁴⁶

Increased risks of depression, anxiety and suicidality have been linked to psoriasis.^{11,12} In PSOLAR, 14.7% and 11.1% of patients reported a history of depression and anxiety, respectively, which is similar to or lower than the proportions reported in phase III studies of biological agents.^{47–50} How-

ever, the proportion of patients with a history of suicidality in PSOLAR was lower (1.0%) than that reported in large surveys conducted by the National Psoriasis Foundation, which were conducted before a number of biological agents were approved for the treatment of psoriasis.⁵¹ Indeed, recent studies have shown that symptoms of anxiety and depression can be reduced, although not eliminated, in patients with psoriasis treated with adalimumab, etanercept, infliximab and ustekinumab.^{46–49} Additionally, data from PSOLAR support the literature, which has shown that certain lifestyle behaviours, such as alcohol use and cigarette smoking, are exhibited more commonly in patients with psoriasis compared with patients without psoriasis and that these behaviours may exacerbate the disease.^{4,12,52}

A subanalysis of medical history by age quartile showed that the proportion of patients with certain comorbidities varied with age. As expected, the prevalence of PsA was lowest among younger patients (aged 18–35 years), given that psoriasis typically develops 10–12 years before PsA.² PSOLAR provides a long-term opportunity to monitor the incidence of PsA, as well as the potential impact of therapies on the development of PsA, in a large psoriasis population prospectively over time. Also, as expected, the proportions of patients with a history of cardiovascular, endocrine, pulmonary and hepatic diseases, as well as skin cancers and other types of cancer, generally increased with age. The proportions of patients with psychiatric illness (e.g. anxiety and depression) were generally comparable across age quartiles, and the proportions using alcohol or smoking cigarettes decreased with age. These observations indicate that, as observed in the general population, age correlates with the occurrence of various comorbid conditions in patients with psoriasis. Whether the treatment of psoriasis with systemic therapies, such as biological agents, may affect associated comorbidities across age groups remains to be seen.

In general, observational data are subject to multiple forms of bias, including treatment selection and outcome reporting bias. In particular, participation bias on the part of the prescriber and the patient may exist, as patients who

choose not to participate are not represented in the registry, and may be reflected in the baseline demographic and comorbidity data presented in this report. Additionally, exposure at baseline may reflect prior treatment selection bias. Enrolment in PSOLAR was driven primarily by North American sites, with > 90.0% of patients from the U.S.A. and Canada. Nonetheless, the PSOLAR population provides valuable insight into the features of a broad group of patients receiving various treatments for psoriasis in the setting of actual clinical care.

In summary, PSOLAR is a large (approximately 12 000 patients), prospective, disease-based registry that represents a valuable resource for collecting information on patient features, disease characteristics, previous treatments and comorbid conditions to further define a profile of patients with psoriasis treated in real-world settings. Additionally, the baseline demographic features and disease characteristics reported at peak historic levels in the registry are generally similar to those reported in clinical trials of biological agents, although some differences are noted. The data presented here (collected from 2007 to 2012) further substantiate that psoriasis is associated with multiple comorbidities⁵³ and indicate that patient age should be considered when evaluating patients with psoriasis for the presence of certain coexisting conditions. PSOLAR is an important part of the safety surveillance programme for ustekinumab and infliximab that is also designed to collect safety data for other biological agents and systemic therapies. Consequently, data collected in the PSOLAR registry will be used to monitor and report long-term safety across a spectrum of psoriasis therapies.

Acknowledgments

We thank Linda Tang, Janssen Research & Development, LLC, Horsham, PA, U.S.A. for her statistical support, and Cynthia Arnold, Janssen Scientific Affairs, LLC, Spring House, PA, U.S.A. for her editorial assistance and writing support.

References

- 1 Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. *Lancet* 2007; **370**:263–71.
- 2 Gladman DD, Antoni C, Mease P *et al.* Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis* 2005; **64** (Suppl. II):ii14–17.
- 3 Wakkee M, Njisten T. Comorbidities in dermatology. *Dermatol Clin* 2009; **27**:137–47.
- 4 Guenther L, Gulliver W. Psoriasis comorbidities. *J Cutan Med Surg* 2009; **13** (Suppl. 2):S77–87.
- 5 Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. *Semin Cutan Med Surg* 2010; **29**:10–15.
- 6 Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. *Nutr Diabetes* 2012; **2**:e54.
- 7 Armstrong A, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation Surveys 2003 to 2011. *Dermatology* 2012; **225**:121–6.

- 8 Kimball AB, Gladman D, Gelfand J *et al.* National Psoriasis Foundation clinical consensus on psoriasis co-morbidities and recommendations for screening. *J Am Acad Dermatol* 2008; **58**:1031–42.
- 9 Davidovici BB, Sattar N, Jorg PC *et al.* Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. *J Invest Dermatol* 2010; **1340**:1785–96.
- 10 Yeung H, Takeshita J, Mehta NN *et al.* Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. *JAMA Dermatol* 2013; **149**:1173–9.
- 11 Kurd SK, Trexel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. *Arch Dermatol* 2010; **146**:891–5.
- 12 Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. *Dermatol Ther* 2010; **23**:174–80.
- 13 Ferver K, Burton B, Jesilow P. The use of claims data in healthcare research. *Open Pub Health J* 2009; **2**:11–24.
- 14 Hartz A, Marsh JL. Methodologic issues in observational studies. *Clin Orthop Relat Res* 2003; **413**:33–42.
- 15 Schmitt-Egenolf M. Psoriasis therapy in real life: the need for registries. *Dermatology* 2006; **213**:327–30.
- 16 Papp KA, Strober B, Augustin M *et al.* PSOLAR: Design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. *J Drugs Dermatol* 2012; **11**:1210–17.
- 17 Gliklich RE, Dreyer NA. *Registries for Evaluating Patient Outcomes: A User's Guide*, 2nd edn. Rockville, MD: Agency for Healthcare Research and Quality, 2010.
- 18 Catanoso M, Pipitone N, Alvarani C. Epidemiology of psoriatic arthritis. *Reumatismo* 2012; **64**:66–70.
- 19 Menter A, Tying SK, Gordon K. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. *J Am Acad Dermatol* 2008; **58**:106–15.
- 20 Lebwohl M, Tying SK, Hamilton TK *et al.* A novel targeted T-Cell modulator, efalizumab, for plaque psoriasis. *N Engl J Med* 2003; **349**:2004–13.
- 21 Leonardi CL, Powers JL, Matheson RT *et al.* Etanercept as monotherapy in patients with psoriasis. *N Engl J Med* 2003; **349**:2014–22.
- 22 Reich K, Nestle FO, Papp K *et al.* Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. *Lancet* 2005; **355**:1367–74.
- 23 Menter A, Feldman SR, Weinstein GD *et al.* A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. *J Am Acad Dermatol* 2007; **56**:31.e1–31.e15.
- 24 Leonardi CL, Kimball AB, Papp KA *et al.* Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet* 2008; **371**:1665–74.
- 25 Papp KA, Langley RG, Lebwohl M *et al.* Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet* 2008; **371**:1675–84.
- 26 Bissonnette R, Searles G, Landells I *et al.* The AWARE study: methodology and baseline characteristics. *J Cutan Med Surg* 2009; **13** (Suppl. 3):S113–21.
- 27 Kimball AB, Pariser D, Yamauchi PS *et al.* OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. *J Am Acad Dermatol* 2013; **68**:756–64.

- 28 Centers for Disease Control and Prevention. QuickStats: prevalence of obesity among persons aged 20–79 years, by sex—Canada, 2007–2009, and United States, 2007–2008. *JAMA* 2011; **306**:1439.
- 29 Shipman AR, Millington GWM. Obesity and the skin. *Br J Dermatol* 2011; **165**:743–50.
- 30 Kim GE, Seidler E, Kimball AB. The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients. *J Eur Acad Dermatol Venerol* 2014; **28**:216–21.
- 31 Christophers E. Comorbidities in psoriasis. *J Eur Acad Dermatol Venerol* 2006; **20**:52–5.
- 32 Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. *J Dermatol* 2012; **39**:212–18.
- 33 Neimann AL, Shin DB, Wang X *et al.* Prevalence of cardiovascular risk factors in patients with psoriasis. *J Am Acad Dermatol* 2006; **55**:829–35.
- 34 Dreiherr J, Weitzman D, Shapiro J *et al.* Psoriasis and chronic obstructive pulmonary disease: a case–control study. *Br J Dermatol* 2008; **159**:956–60.
- 35 Yang Y-W, Keller JJ, Lin H-C. Medical comorbidity associated with psoriasis in adults: a population-based study. *Br J Dermatol* 2011; **165**:1037–43.
- 36 Landgren E, Braback L, Hedlin G *et al.* Psoriasis in Swedish conscripts: time trend and association with T-helper 2-mediated disorders. *Br J Dermatol* 2006; **154**:332–6.
- 37 Poupard C, Brenaut E, Horreau C *et al.* Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. *J Eur Acad Dermatol Venerol* 2013; **27**:36–46.
- 38 Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? *Dermatol Ther* 2009; **22**:418–30.
- 39 Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. *N Engl J Med* 2005; **353**:2262–9.
- 40 Archier E, Devaux S, Castela E *et al.* Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systemic literature review. *Eur Acad Dermatol Venerol* 2012; **26** (Suppl. 3):22–31.
- 41 Miele L, Vallone S, Cefalo C *et al.* Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. *J Hepatol* 2009; **51**:778–86.
- 42 Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: A study from South India. *Aust J Dermatol* 2012; **53**:190–7.
- 43 Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present, and future. *Clin Exp Dermatol* 2013; **38**:573–88.
- 44 Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. *Gastroenterol* 2005; **129**:827–36.
- 45 Lees CW, Barrett JC, Parkes M *et al.* New IBD genetics: common pathways with other diseases. *Gut* 2011; **60**:1739–53.
- 46 Cohen AD, Dreiherr J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. *J Eur Acad Dermatol Venerol* 2009; **23**:561–5.
- 47 Tyring S, Gottlieb A, Papp K *et al.* Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. *Lancet* 2006; **367**:29–35.
- 48 Langley RG, Feldman SR, Han C *et al.* Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. *J Am Acad Dermatol* 2010; **63**:457–65.
- 49 Feldman SR, Gottlieb AB, Bala M *et al.* Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. *Br J Dermatol* 2008; **159**:704–10.
- 50 Menter A, Augustin M, Signorovitch J *et al.* The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. *J Am Acad Dermatol* 2010; **62**:812–18.
- 51 Menter A, Gottlieb A, Feldman SR *et al.* Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol* 2008; **58**:826–50.
- 52 Fortes C, Mastroeni S, Leffondre K *et al.* Relationship between smoking and the clinical severity of psoriasis. *Arch Dermatol* 2005; **141**:1580–4.
- 53 Gulliver WP, MacDonald D, Gladney N *et al.* Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador Founder population. *J Cutan Med Surg* 2011; **15**:37–47.

Appendix 1

Conflicts of interest

A.B.K. is an investigator and consultant for Amgen, AbbVie, Janssen, Pfizer, Merck and Celgene. She is a consultant to VBL Therapeutics and also has fellowship funding from Janssen. C.L. has served as a consultant, investigator and/or speaker for AbbVie, Amgen, Celgene, Centocor, Eli Lilly, Galderma, Genentech, Genzyme, GlaxoSmithKline, Incyte, Janssen, Maruho, Novartis, Novo Nordisk, Pfizer, Schering Plough, Sirtris, Stiefel, Vascular Biogenics and/or Wyeth. M.S. has received research support or has served as a speaker or advisory board member for Pfizer, AbbVie, Novartis, Janssen-Cilag, MSD and Leo Pharma. W.G. has received speaker honoraria and consulting fees, conducted clinical trials and/or served on Advisory Boards for AbbVie, Amgen, Astellas, Celgene, Janssen, Merck, Novartis and Pfizer. A.M. has received grants and/or honoraria as an advisory board member, consultant, investigator and/or speaker for AbbVie, Allergan, Amgen, ApoPharma, Boehringer, Celgene, Convoy Therapeutics, Inc, Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Symbio/Maruho, Syntrix Biosystems, Wyeth, and/or XenoPort. M.C., S.F., K.G. and S.C. are employees of Janssen Scientific Affairs LLC, and W.L. is an employee of Janssen Research & Development, LLC.

Appendix 2

Psoriasis Longitudinal Assessment and Registry Steering Committee members

The Psoriasis Longitudinal Assessment and Registry Steering Committee members include M. Augustin, Institute for Health Services Research in Dermatology, University Medical Center Hamburg–Eppendorf, Hamburg, Germany; M. Chevrier, Janssen Scientific Affairs, Horsham, PA, U.S.A.; D. Fiorentino, Stanford University School of Medicine, Stanford, CA, U.S.A.;

J. Gelfand, University of Pennsylvania, Philadelphia, PA, U.S.A.; A.B. Gottlieb, Tufts Medical Center and Tufts School of Medicine, Boston, MA, U.S.A.; V. Ho, University of British Columbia, Vancouver, BC, Canada; R. Kalb, State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, U.S.A.; F.A. Kerdel, Florida Academic Dermatology Centers, Miami, FL, U.S.A.; A.B. Kimball, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.; G.G. Krueger, University of Utah School of Medicine, Salt Lake City, UT, U.S.A.; R. Langley, Dalhousie

University, Halifax, NS, Canada; M. Lebwohl, Mount Sinai School of Medicine, New York, NY, U.S.A.; C.L. Leonardi, Saint Louis University Medical Center, St. Louis, MO, U.S.A.; A. Menter, Baylor University Medical Center, Dallas, TX, U.S.A.; L. Naldi, Centro Studi GISED, Bergamo, Italy; Kim Papp, Clinical Research Inc., Waterloo, ON, Canada; D. Pariser, Eastern Virginia Medical School and Virginia Clinical Research, Norfolk, VA, U.S.A.; B. Strober, University of Connecticut School of Medicine, Farmington, CT, U.S.A.